S 81694 Plus Paclitaxel in Metastatic Breast Cancer
- First Posted Date
- 2018-01-26
- Last Posted Date
- 2021-05-25
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 22
- Registration Number
- NCT03411161
- Locations
- 🇧🇪
UZ Leuven Campus Gasthuisberg Dept. of General Medical, Leuven, Belgium
🇯🇵Chiba cancer center Breast surgery, Chiba, Japan
🇯🇵Osaka International Cancer Institute, Osaka, Japan
Study of AG-120 and AG-881 in Subjects With Low Grade Glioma
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 49
- Registration Number
- NCT03343197
- Locations
- 🇺🇸
United States, New York, New York, New York, United States
🇺🇸United States, California, San Francisco, California, United States
🇺🇸United States, Massachusetts, Boston, Massachusetts, United States
A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Cancer That Has Spread (Metastatic).
- Conditions
- Interventions
- First Posted Date
- 2017-10-11
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 907
- Registration Number
- NCT03306394
- Locations
- 🇧🇪
Cliniques Universitaires St. Luc Oncologie médicale, Bruxelles, Belgium
ðŸ‡ðŸ‡·Klinicki bolnicki centar Zagreb Klinika za onkologiju, Zagreb, Croatia
🇵🇱Centrum Onkologii - Instytut im. Marii Sklodowskiej-Curie Klinika Gastroenterologii Onkologicznej, Warszawa, Poland
Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Failed Standard Chemotherapies
- First Posted Date
- 2017-09-07
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 26
- Registration Number
- NCT03274882
- Locations
- 🇷🇺
Russian Cancer Research Center n.a. NN Blokhin (RCRC), Clinical Pharmacology and Chemotherapy department, Moscow, Russian Federation
🇷🇺Saint Petersburg Clinical Scientific-Practical Center of Special Medical Care (Oncology Center), Saint Petersburg, Russian Federation
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
- Conditions
- Interventions
- First Posted Date
- 2017-06-01
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 146
- Registration Number
- NCT03173248
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇮🇱Shamir Medical Center Assaf Harofeh, Tzrifin, Israel
🇺🇸Norton Cancer Institute - Suburban, Louisville, Kentucky, United States
Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)
- Conditions
- Interventions
- First Posted Date
- 2016-12-12
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 187
- Registration Number
- NCT02989857
- Locations
- 🇺🇸
University of California, Irvine, Irvine, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2016-12-01
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 38
- Registration Number
- NCT02979366
- Locations
- 🇦🇺
The Alfred Hospital Department of Haematology, Melbourne, Australia
🇦🇺Royal Melbourne Hospital, Department of Clinical Haematology and BMT Service, Melbourne, Australia
🇫🇷Institut Paoli-Calmettes Departement d'Hématologie, Marseille, France
Dose-escalation Study of Oral Administration of S 055746 in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2016-09-30
- Last Posted Date
- 2019-05-24
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 48
- Registration Number
- NCT02920541
- Locations
- 🇫🇷
Institut Paoli Calmettes, Marseille, France
🇦🇺Royal Melbourne Hospital, Parkville, Australia
🇦🇺The Alfred Hospital, Melbourne, Australia
Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2016-09-30
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 65
- Registration Number
- NCT02920697
- Locations
- 🇸🇬
National University Cancer Institute Singapore, Singapore, Singapore
ðŸ‡ðŸ‡ºCRU Hungary Kft, Miskolc, Hungary
🇵🇱Warsaw Medical University, Warsaw, Poland
Efficacy and Safety Trial With S 44819 After Recent Ischemic Cerebral Event
- Conditions
- Interventions
- First Posted Date
- 2016-08-24
- Last Posted Date
- 2020-03-11
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 585
- Registration Number
- NCT02877615
- Locations
- 🇵🇱
Wojewodzki Szpital Specjalistyczny SPZOZ nr 3 w Rybniku, Rybnik, Poland
🇵🇱Instytut Psychiatrii i Neurologii II Klinika Neurologiczna, Warszawa, Poland
🇵🇱Szpital Specjalistyczny Ducha Swietego w Sandomierzu Oddzial Neurologii, Sandomierz, Poland